383 related articles for article (PubMed ID: 20064953)
1. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
4. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
Decaux G
J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
[TBL] [Abstract][Full Text] [Related]
5. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
7. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
9. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
Marik PE; Rivera R
Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
[TBL] [Abstract][Full Text] [Related]
12. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
13. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
14. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
15. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Wong F; Blei AT; Blendis LM; Thuluvath PJ
Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approach in patients with dysnatraemias.
Liamis G; Kalogirou M; Saugos V; Elisaf M
Nephrol Dial Transplant; 2006 Jun; 21(6):1564-9. PubMed ID: 16449285
[TBL] [Abstract][Full Text] [Related]
17. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan.
Sughrue ME; McDermott M; Blevins LS
J Clin Neurosci; 2010 Oct; 17(10):1331-4. PubMed ID: 20594854
[TBL] [Abstract][Full Text] [Related]
18. Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury.
Human T; Onuoha A; Diringer M; Dhar R
J Crit Care; 2012 Dec; 27(6):745.e1-5. PubMed ID: 22520494
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
20. Use of conivaptan for refractory syndrome of inappropriate secretion of antidiuretic hormone in a pediatric patient.
Peters S; Kuhn R; Gardner B; Bernard P
Pediatr Emerg Care; 2013 Feb; 29(2):230-2. PubMed ID: 23546432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
